Download Files:
BMS-986251
$1,040 – $15,400
Products Details
Product Description
– BMS-986251 is an orally active and selective RORγt inverse agonist with an EC50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis)[1].
Web ID
– HY-136527
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C30H29F8NO5S
References
– [1]Robert J. Cherney, et al. Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist. ACS Med. Chem. Lett. 2020, 11, 6, 1221–1227
CAS Number
– 2460133-35-9
Molecular Weight
– 667.61
SMILES
– O=C([C@H]1C[C@H](C)[C@H](C(N2CC[C@@]3(S(=O)(C4=CC=C(F)C=C4)=O)C5=CC=C(C(C(F)(F)F)(F)C(F)(F)F)C=C5CC[C@@]23[H])=O)CC1)O
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Interleukin Related;ROR
Isoform
– IL-17;RORα;RORβ;RORγ
Pathway
– Immunology/Inflammation;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
